Acquired haemophilia A following COVID-19 vaccine

Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure. Both events were preceded by a COVID-19 mRNA booster vaccination. Laboratory data was significant for a prolonged activated partial thromboplastin time (aPTT) of 55 s which prompted a haematology consult. A further work-up revealed the presence of an acquired FVIII inhibitor correlating with a severely reduced activity level. Treatment was given to eradicate the inhibitor with steroids and cyclophosphamide, while a thorough investigation was initiated for possible causes. Prompt recognition of an acquired inhibitor is essential for timely management to control bleeding.

Authors

Institutions

Publication Details

Journal
BMJ Case Reports
Published
2025-03-01
DOI
https://doi.org/10.1136/bcr-2024-263299
Citations
1
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
1.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acquired haemophilia A following COVID-19 vaccine

Samah Nassereddine, Omar Yaghi, Jennifer Kate Beckerman
1 citations
BMJ Case Reports
Hemophilia Treatment and Research
1.77
article

Acquired haemophilia A following COVID-19 vaccine

Samah Nassereddine, Omar Yaghi, Jennifer Kate Beckerman
article en
1 citations

Abstract

Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure. Both events were preceded by a COVID-19 mRNA booster vaccination. Laboratory data was significant for a prolonged activated partial thromboplastin time (aPTT) of 55 s which prompted a haematology consult. A further work-up revealed the presence of an acquired FVIII inhibitor correlating with a severely reduced activity level. Treatment was given to eradicate the inhibitor with steroids and cyclophosphamide, while a thorough investigation was initiated for possible causes. Prompt recognition of an acquired inhibitor is essential for timely management to control bleeding.

BMJ Case ReportsVol. 18(3)
George Washington University Hospital (US)
Openalex Percentile: Top 18%
Hemophilia Treatment and Research
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Acquired haemophilia A following COVID-19 vaccine — Samah Nassereddine, Omar Yaghi, et al. · BMJ Case Reports (2025) | TGRS Research Map | TGRS